✦ LIBER ✦

PAR8 LEFLUNOMID VERSUS CYCLOSPORIN IN METHOTREXATE-RESISTANT RHEUMATOID ARTHRITIS IN POLAND:A COST-EFFECTIVENESS ANALYSIS

✍ Scribed by D Golicki; M Niewada; J Lis; B Kaminski; M Jakubczyk; T Macioch

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PAR4 ETANERCEPT VERSUS INFLIXIMAB PLUS M

✍ S Lopatriello; P Berto 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

PAR11 COST-EFFECTIVENESS OF ADDING LEFLU

✍ D Golicki; M Niewada; J Lis; T Macioch 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

PMS4 COST-EFFECTIVENESS ANALYSIS OF LEFL

✍ F Carlos-Rivera; A Aguirre-Granados; SOMC Manterola 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

PAR4 COST-EFFECTIVENESS ANALYSIS OF RITU

✍ D Porter; G Lewis; B Brown; A Diamantopoulos; A Kielhorn 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

PMS8 Cost-Effectiveness analysis of Etan

✍ Lutz, M.; Cuesta, G.; Morales, G. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

PAR14 COST MINIMIZATION ANALYSIS OF RITU

✍ MG Saggia; EA Santos; V Nasciben 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB